Research record / starter review

AOD-9604

Growth-hormone fragment discussed in body-composition communities

Tested-sport concernLast reviewed 2026-07-13

Also called

AOD 9604 · hGH 176-191 fragment

What people ask about

Community claims

fat-loss claimsbody-composition claims

These are topics circulating in appearance, physique, or recovery communities. Listing them does not validate them.

What this record can say

Evidence snapshot

FDA meeting material summarising historical obesity studies states that the clinical studies reviewed did not show statistically significant weight loss versus placebo and notes limited underlying reporting. This does not test recovery or joint claims.

Safety context

Read uncertainty as information

FDA describes potential immunogenicity and peptide-characterisation concerns, says it has no or limited safety information, and notes serious adverse events that may be associated with the substance without establishing causality.

Tested sport

Anti-doping context

WADA's 2026 List names AOD-9604 as an example of a growth-hormone fragment in S2.2.3.

Regulatory scope

Context is not a universal answer

United States: this reflects FDA's compounding-safety source, not a global legal determination.

Study-level evidence

What the individual records actually say.

Every row preserves identity and context. A related molecule, a tissue experiment, or a trial registration cannot become proof for the community claim.

FDA meeting-material evidence summary2024

AOD-9604 evidence discussion in FDA Pharmacy Compounding Advisory Committee meeting materials ↗

FDA, December 4, 2024 Pharmacy Compounding Advisory Committee meeting materials.

Identity: Exact compound name: AOD-9604

Design & population: FDA materials summarise several small and larger historical obesity studies, noting limited reporting detail in the underlying publications and submissions.

Question studied: Historical obesity/weight-loss development evidence and safety information considered in a compounding-safety context.

Record finding: The FDA material states that the clinical studies it summarises did not show statistically significant weight loss compared with placebo and flags methodological/reporting limitations.

Does not show: This is not a substitute for complete primary reports, and it does not establish efficacy or safety for body-composition, joint, recovery, or other community claims.

Official secondary evidence summary — limited underlying reportingChecked 2026-07-13

Primary sources

Read the source, not only our summary.

regulatory / safetyCertain Bulk Drug Substances for Use in Compounding that May Present Significant Safety RisksU.S. Food and Drug Administration ↗anti-doping2026 Prohibited ListWorld Anti-Doping Agency ↗